SYRE

Spyre Therapeutics, Inc.
CAPPED RATING

Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer.

Spyre Therapeutics, Inc. (SYRE) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -28.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -0.6%
Price Return 12M 343.9%
Catalyst Signal 0.00
Market Cap $9.9B
TTM Revenue N/A
Price / Sales N/A
ROE -35.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D (1.4) D (1.4) C+ (2.7) C+ (2.6) C- (2.1)
2026-11-08 C+ (2.5) D (1.4) D (1.4) C+ (2.8) C+ (2.6) C- (2.1)
2026-11-01 C+ (2.5) D (1.4) D (1.4) B- (3.0) C+ (2.7) C (2.2)
2026-10-25 C+ (2.5) D (1.4) D (1.4) B- (2.9) F (0.0) D+ (1.6)
2026-10-18 C+ (2.5) D (1.4) D (1.4) B- (2.9) F (0.0) D+ (1.6)
Page 1 of 3